Source link : https://newshealth.biz/health-news/does-destiny-breast09-change-first-line-care-in-her2-positive-breast-cancer/
The DESTINY-Breast09 trial, presented at this year’s American Society of Clinical Oncology annual meeting, established trastuzumab deruxtecan (T-DXd; Enhertu) plus pertuzumab (Perjeta) as a new first-line treatment option for patients with HER2-positive metastatic breast cancer, while raising new questions about patient selection and treatment duration. MedPage Today brought together three expert leaders in the field: […]
The post Does DESTINY-Breast09 Change First-Line Care in HER2-Positive Breast Cancer? first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-30 16:10:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8